Eli Lilly is negotiating with Australia’s Pharmaceutical Benefits Scheme to make the GLP-1 drug Mounjaro available under the national subsidy program [1].
The outcome of these talks will determine whether thousands of Australians can access the diabetes and obesity medication at a subsidized cost or must pay full price.
CEO David Ricks said the company is still looking to bring the medication to the Australian market [1]. This comes after a previous attempt to reach an agreement ended when the company walked away from the table over pricing disagreements [2].
According to the company, the pricing offer provided by the Pharmaceutical Benefits Scheme is below what Eli Lilly considers appropriate for modern drug development [2]. The company maintains that the cost of bringing new medications to market requires a pricing structure that reflects those investments [2].
Despite the prior impasse, Ricks said the door remains open for further discussions [1]. The company continues to engage with Australian health authorities to find a mutually acceptable price that allows the drug to be listed on the PBS [1].
Mounjaro belongs to a class of GLP-1 receptor agonists used to treat type 2 diabetes and chronic weight management [2]. These drugs have seen a global surge in demand, often leading to supply constraints and intense pricing negotiations between manufacturers and government health bodies [2].
The Pharmaceutical Benefits Scheme is the primary mechanism the Australian government uses to ensure affordable access to necessary medicines [1]. If a drug is not listed on the PBS, patients must pay the full market price, which can be prohibitively expensive for many users [1].
“Eli Lilly is still looking to bring the medication to the Australian market.”
This standoff highlights a growing global tension between pharmaceutical companies and national health systems over the cost of GLP-1 medications. As demand for obesity and diabetes treatments spikes, governments are pushing for lower costs to maintain budget sustainability, while manufacturers argue that high prices are necessary to fund future research and development. The resolution of these talks will serve as a benchmark for how high-cost, high-demand specialty drugs are priced in the Australian market.
